维多珠单抗与阿达木单抗早期应答者与延迟应答者的长期结局:VARSITY 研究的事后分析
该研究为 VARSITY 研究的事后分析,比较中重度溃疡性结肠炎患者中维多珠单抗与阿达木单抗早期与延迟部分 Mayo 评分缓解者的临床结局。维多珠单抗早期缓解者第 52 周临床缓解与组织内镜下黏膜改善的 odds 高于延迟缓解者,阿达木单抗组无差异。
要点
- 维多珠单抗早期部分 Mayo 评分缓解者第 52 周临床缓解率高于延迟缓解者。
- 维多珠单抗早期缓解者第 52 周组织内镜下黏膜改善率高于延迟缓解者。
- 阿达木单抗早期与延迟缓解者第 52 周临床缓解、内镜改善及组织内镜下黏膜改善均无差异。
核心结论
- 接受维多珠单抗治疗达到早期部分 Mayo 评分缓解的溃疡性结肠炎患者,第 52 周缓解的 odds 高于延迟应答者。
研究设计与样本
- VARSITY 研究的事后分析,纳入 147 例维多珠单抗治疗和 110 例阿达木单抗治疗达到早期或延迟部分 Mayo 评分缓解的患者。
主要发现
- 维多珠单抗早期部分 Mayo 评分缓解者第 52 周临床缓解率为 69.1%(67/97),延迟缓解者为 50.0%(25/50),aOR 2.43(95% CI 1.11-5.33),P=0.027。
- 维多珠单抗早期部分 Mayo 评分缓解者第 52 周组织内镜下黏膜改善率为 63.9%(62/97),延迟缓解者为 40.0%(20/50),aOR 2.60(95% CI 1.20-5.62),P=0.015。
- 维多珠单抗早期与延迟部分 Mayo 评分缓解者第 52 周内镜改善率相似。
- 阿达木单抗早期与延迟部分 Mayo 评分缓解者第 52 周临床缓解、内镜改善及组织内镜下黏膜改善均无差异。
关键数值与推荐
- 早期部分 Mayo 评分缓解定义为治疗第 4/6 周部分 Mayo 评分≤1。
- 延迟部分 Mayo 评分缓解定义为第 14 周部分 Mayo 评分≤1 且第 4/6 周未达≤1。
- 第 52 周临床缓解定义为部分 Mayo 评分=0。
- 内镜改善定义为 Mayo 内镜评分≤1。
- 组织内镜下黏膜改善定义为 Mayo 内镜评分≤1 且 Geboes 评分最高分级<3.2。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: It is uncertain whether patients with ulcerative colitis (UC) and delayed symptomatic response to therapy have as robust and durable a response as earlier responders to therapy. We compared clinical outcomes of early and delayed responders to vedolizumab and adalimumab for patients with moderate-severe UC. METHODS: This was a post hoc analysis of the VARSITY study. Patients with early partial Mayo score (PMS) remission (PMS ≤1 at week 4/6 of therapy) were compared with those with delayed PMS remission (PMS ≤1 at week 14 and not week 4/6). Differences in proportions of patients achieving week 52 clinical remission (CR) (PMS = 0), endoscopic improvement (EI) (Mayo endoscopic subscore ≤1), and histoendoscopic mucosal improvement (HEMI) (Mayo endoscopic subscore ≤1 and Geboes score highest grade <3.2) were assessed. Confounders were adjusted for using multivariate logistic regression. RESULTS: A total of 147 vedolizumab-treated and 110 adalimumab-treated patients attained early or late PMS remission. Those who attained early PMS remission with vedolizumab were more likely to attain week 52 CR than participants with delayed PMS remission with vedolizumab (69.1% [67/97] vs 50.0% [25/50], aOR 2.43 [95% CI 1.11-5.33], P = 0.027). Week 52 HEMI was more likely among early vedolizumab PMS remitters (63.9% [62/97] vs 40.0% [20/50], aOR 2.60 [95% CI 1.20-5.62], P = 0.015). Week 52 EI was similar between early and delayed PMS remitters to vedolizumab. No differences were observed in week 52 CR, EI, or HEMI between early and delayed PMS remitters to adalimumab. DISCUSSION: Patients with UC who achieve early PMS remission with vedolizumab have greater odds of week 52 remission compared with delayed responders.
引用
- Narula N, Wong ECL, Marshall JK, et al. Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study. Am J Gastroenterol. 2022. PMID: 36066459. doi:10.14309/ajg.0000000000001987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。